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Xanthones of natural and synthetic origin are
of biological and pharmacological interest. In
dependence on the kind and place of substitution in
one of the xanthone rings, a large variety of phar-
macological activities were reported (1-9). Two syn-
thetic compounds, named xanthonolol (3-[3-(propy-
lamino)-2-hydroxypropoxy]xanthone) and 3-hydro-
xyxanthone reduced the blood pressure, heart rate,
and L-isoproterenol-induced tachycardia in rats
(10). We herein report on the preparation and antiar-
rhythmic, antihypertensive as well as anticonvulsant
activity of a few appropriate aminoisopropanoloxy
derivatives of 4-xanthone containing 1-(2-hydro-
xyethyl)-piperazine, ethylpiperazine-1-carboxylate
and 1-(benzyl)-piperazine moieties (II ñ IV).
Previously, some of appropriate aminoisopropano-
loxy derivatives of 2-, 3- or 2-methyl-6-xanthone as
well as aminoalkanolic derivatives of 7-chloro-2-
methylxanthone had been tested for their effects on
the circulatory system, influence on the non-work-
ing heart perfusion, antiarrhythmic activity in exper-
imentally adrenaline induced arrhythmia, as well as




Melting points are uncorrected and were deter-
mined on a B¸chi SMP-20 apparatus. Microanalyses
for C, H, N were performed in the Department of
Pharmaceutical Chemistry, Medical College, the
Jagiellonian University. All the results were within
(±) 0.4% of the theoretical values. The IR spectra
were recorded on a Perkin-Elmer spectrometer, the
samples were prepared as KBr pellets. The 1HNMR
spectra were recorded on a Bruker spectrometer
with 300 MHz in DMSO-[d6] using tetramethylsi-
lane (TMS) as an internal standard. TLC was per-
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Abstract: Some of appropriate aminoisopropanoloxy derivatives of 4-xanthone were tested for their effect on
circulatory system (protection against adrenaline-, barium-, and calcium chloride-induced arrhythmias, as well
as hypotensive activity and acute toxicity). The most prominent hypotensive activity was demonstrated by 
(±)-1-[4-(hydroxyethyl)-1-(piperazinyl)]-3-(4-xanthonoxy)-2-propanol dihydrochloride (II), which diminished
arterial blood pressure by about 40% during one hour observation. The investigated compounds did not prevent
adrenaline- and barium-induced arrhythmias. In calcium-induced model of arrhythmia compound II slightly
intensified blocks (about 7%), but delayed extrasystoles (37%), efficiently prevented bigeminy (70%, p < 0.01)
and diminished (53%, p < 0.05) mortality of animals. All investigated compounds decreased heart rate by 10 ñ
18%, prolonged P-Q section, QRS complex and Q-T interval. The most potent and significant negative
chronotropic effect and markedly prolonged duration of P-Q section was demonstrated by compound II. The
influence of investigated compounds on ECG components suggests that activity of compound IV is similar to
class 1a anti-arrhythmic compounds according to Voughan-Williams classification of antiarrhythmic drugs,
because of prolongation of P-Q and Q-T intervals and extension of QRS complex. Compounds II and IV were
also evaluated for anticonvulsant activity in the maximal electroshock seizures (MES) and subcutaneous
pentylenetetrazole seizure threshold (ScMet) assays and for neurotoxicity (TOX). The anti-MES activity in
mice was found for IV, which in a dose of 100 mg/kg within 0.5 h after ip administration showed 75% anti-
convulsant protection with 50% neurotoxicity.
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formed on silica gel GF254 precoated plates (5 ◊ 10
cm, 0.25 mm, Merck) with an appropriate developing
system (CHCl3/MeOH, 1 : 1, v/v); spots were visual-
ized with the UV light. The starting compound (I) (4-
[(2,3-epoxy)propoxy]xanthone) was obtained from 4-
hydroxyxanthone, according to the earlier described
procedure (15, 16). Reagents and solvents were com-
mercially available materials of reagent grade.
General procedure for the preparation of compounds
II ñ IV
Compounds II ñ IV were obtained by amina-
tion of I with appropriate 1-piperazine derivatives in
n-propanol (Scheme 1), according to the earlier pub-
lished procedures (15, 16). The resulted bases were
converted into hydrochloride salts in propanol/ace-




Yield: 62%, m.p. 256-258OC (acetone/ethanol
1 : 1, v/v), Rf = 0.39 (base: m.p. 118-120OC (etha-
nol)); C22H28Cl2N2O5 (471.37). 1H NMR (δ, ppm):
12.62 (2H, bb, NH+), 8.21 (1H, dd, J = 1.7 Hz, J =
8.0 Hz, H-8), 7.92-7.12 (6H, m, H-Ar), 6.21 (1H, bs,
CHOH), 4.53-4.40 (1H, m, CH), 4.44 (1H, bb,
CH2OH), 4.22-4.12 (2H, m, CH2OH), 4.08-2.98
(14H, m, N(CH2)6, OCH2), IR (ν [cm-1]): 3312,
3007, 2942, 2638, 2440, 1657, 1617, 1607, 1594,
1495, 1451, 1342, 1278, 1232.
(±)-1-[4-(Ethoxycarbonyl)-1-(piperazinyl)]-3-[4-
xanthonoxy)-2-propanol hydrochloride (III)
Yield: 54%, m.p. 190-192OC (n-propanol), Rf =
0.90 (base: m.p. 138-140OC (ethanol); C23H27ClN2O6
(462.92). 1H NMR-base (δ, ppm): 8.28 (1H, dd, J =
1.6 Hz, J = 8.0 Hz, H-8), 7.74-7.28 (6H, m, H-Ar),
5.89 (1H, bs, OH), 4.36-4.24 (1H, m, CH), 4.19 (2H,
q, J = 7.2 Hz, CH2(Et)), 4.10-4.05 (2H, m, OCH2),
3.62-2.64 (10H, m, N(CH2)5), 1.32 (3H, t, J = 7.2
Hz, CH3(Et)). IR (ν [cm-1]): 3067, 2981, 1711, 1631,
1617, 1593, 1492, 1443, 1269, 1231.
(±)-1-[4-(Benzyl)-1-(piperazinyl)]-3-(4-xanthoxy)-
2-propanol dihydrochloride (IV)
Yield: 61%, m.p. 247-249OC, Rf = 0.38,
C27H30Cl2N2O4 (517.44), 1H NMR (δ, ppm): 12.55
(1H, bb, NH+), 11.6 (1H, bb, NH+), 8.19-8.13 (1H,
m, H-8), 7.88-7.40 (10H, m, H-Ar), 5.76 (1H, bs,
OH), 4.51-4.45 (2H, m, CH2-Ph), 4.40-4.28 (1H, m,
CH), 4.12-4.08 (2H, m, OCH2), 3.86-3.24 (10H, m,
N(CH2)5). IR (ν [cm-1]): 3357, 2991, 2506, 2420,
1642, 1606, 1593, 1494, 1469, 1344, 1284, 1228.
PHARMACOLOGY
Animals
The studies were carried out on male albino
Swiss mice weighing 18 ñ 24 g (purchased from a
licensed dealer; Hurlak, KrakÛw, Poland), nor-
motensive male Wistar rats weighing 170 ñ 250 g,
and guinea-pigs weighing 300 ñ 350 g. The animals
Scheme 1. Synthesis and structures of the title compounds.
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were kept in plastic cages in a room at a temperature
of 20 ± 4OC, under 12/12 h light/dark cycle (light on
from 7 a.m. to 7 p.m.). They were fed with granulat-
ed feed (standard laboratory pellets; Bacutil,
Motycz, Poland) and had free access to water. The
control and study groups consisted of 6-8 animals
each. Treatment of the used laboratory animals in
the present study was in full accordance with the
respective Polish and European regulations and was
approved by the Local Ethics Committee. The
European Convention for protection of the verte-
brate animals, used for experimental studies as well
as different scientific aims (European Convention)
undersigned in Strasburg in 1983, ascertains that in
existing conditions is not possible to give up using
laboratory animals for the scientific studies. The
databases should be created to enable utilization by
researches the information from homologous fields
in regard to use laboratory audits limitation of the
animalsí quantity. In our studies comparing pharma-
cological activities of new compounds, with the
well-known drugs used as reference compounds,
results of our previous experiments in Department
of Pharmacodynamics, Jagiellonian University
Medical College were exploited. The utilization of
previous results, is postulated by the European
Convention ñ as the sui generis database, what is in
accord with general recommendations in matter of
the vertebrate animalsí protection (17).
Drugs
The following drugs were used: adrenaline
hydrochloride (Polfa, Poland), thiopental sodium
(Spofa, Czech Republic), heparin sodium (Roche,
France), propranolol (Polfa, Poland), calcium chlo-
ride (POCh, Poland), barium chloride (POCh,
Poland), quinidine (Polfa, Poland). The investigated
compounds were dissolved or diluted in 0.9% sodium
chloride isotonica (Rhone-Poulenc Rorer, France).
Acute toxicity according to Deichmann (18)
The experiments were carried out on male albi-
no Swiss mice (20 ñ 25 g) The compounds dissolved
in 0.9% saline, were injected into the caudal vein (1
mL/kg). Each dose was given to 6 animals. The
LD50 were calculated acc. to the method of
Litchfield and Wilcoxon after 24 h observation peri-
od (19).
The effect on normal electrocardiogram
Electrocardiographic studies were carried out
on anesthetized rats using a Multicard E-30 appara-
tus. ECG was recorded from the second extremity
lead at a tape speed of 50 mm/s. The influence of the
compounds studied on the frequency of myocardiac
contraction, the P wave and QRS complex were
determined.
Adrenaline-induced arrhythmia according to Sze-
keres (20)
The arrhythmia was evoked in rats anes-
thetized with thiopental (75 mg/kg, ip) by iv injec-
tion of adrenaline (20 µg/kg, in a volume of 1 mL/kg
of animal weight). The studied compounds were
administered intravenously 15 min before adrena-
line. Evaluation of the antiarrhythmic activity was
made acc. to the time of occurring postadrenaline
disorders and the survival time of animals in control
and studied group. ECG was recorded on a Multi-
card E-3 or E-30 apparatus, using the standard limb
lead, and the tape speed 50 mm/s.
Calcium chloride-induced arrhythmia according to
Szekeres (20)
In order to evoke arrhythmia, calcium chloride
in a dose of 150 mg/kg was administered iv in a vol-
ume of 1 mL/kg. Attenuation or the lack of distur-
bances and the decreased mortality after calcium
chloride were accepted as a criterion of the antiar-
rhythmic effect of the investigated compounds in
comparison with the control group.
Barium chloride-induced arrhythmia according to
Szekeres (20)
Barium chloride solution was injected into the
caudal vein of rat (32 mg/kg, in a volume of 1
mL/kg). The investigated compound was given iv 15
min before the arrhythmogen. The criterion of
antiarrhythmic activity was a gradual disappearance
of the arrhythmia and restoration of the sinus rhythm
in comparison with the control group.
The effect on the arterial blood pressure and respira-
tory movements
Measurements were carried out on normoten-
sive rats. The animals were anesthetized with ip
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thiopental administration at a 75 mg/kg
dosage. Blood pressures were recorded in
the left common carotid artery using an
electromanometer of type EK-4 together
with a Watanabe recorder WTR-331. The
examined compounds dissolved in 0.9%
sodium chloride were administered to rat
tail vein in a range of dosage 1/20 ñ 2/5
LD50. Simultaneous blood pressure meas-
urements and changes in respiration were
recorded.
Anticonvulsant assays
Antiepileptic activity and neurological
toxicity assays were carried out by the
Antiepileptic Drug Development Program,
Epilepsy Branch, National Institute of
Neurological and Communicative Disor-
ders and Stroke, National Institute of
Health, Bethesda, MD, USA. The com-
pounds were injected ip into mice as sus-
pensions in 0.5% methylcellulose at three
dosage levels (30, 100 and 300 mg/kg). The
MES were elicited by 60 Hz alternating
current of 50 mA for 0.2 s via corneal elec-
trodes. A drop of 0.9% NaCl solution was
instilled in each eye prior to application of
the electrodes. Abolition of the hindlimb
tonic extensions component of the seizure
was defined as protection in the MES test.
The ScMet test was conducted by adminis-
tering 85 mg/kg of pentylenetetrazole dis-
solved in 0.9% NaCl solution in the poste-
rior midline of mice. A minimal time 30
min subsequent to sc administration of
pentylenetetrazole was used for seizure
detection. A failure to observe even a
threshold seizure (a single episode of clonic
spasm of at least 5 s duration) was regarded
as protection. Neurological deficit was
measured in mice by the rotorod test. The
mouse was placed on 1 inch diameter
knurled plastic rod rotating at 6 rpm.
Neurotoxicity was indicated by the inabili-
ty of the animal to maintain equilibrium on
the rod for at least 1 min in each of three tri-
als. The more details of the evaluation pro-
cedure have been published ( 22, 23).
Statistical analysis
The data are expressed as the means ±
SEM. Studentís t-test or Fisherís two-tailed
exact probability test were used to deter-
mine the significance of differences
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between the mean values of the control and treat-
ment groups. Differences were considered signifi-
cant when p was < 0.05.
RESULTS AND DISCUSSION
Acute toxicity according to Deichmann
The LD50 values for investigated aminoalka-
nolic derivatives II ñ IVa, determined in mice
after intravenous administration, are presented in
Table 1.
The effect on normal electrocardiogram
All the investigated compounds decreased
heart rate by 10 ñ 18%, prolonged the duration of 
P-Q section, the QRS complex and the Q-T interval.
The strongest negative chronotropic effect (p <
0.001) and the most prolonged duration of P-Q sec-
tion were of compound II. In summary, the influ-
ence of the investigated compounds on ECG com-
ponents, suggested that activity of compound IV is
similar to class 1a antiarrhythmic compounds
according to Voughan-Williams, because of the pro-
Table 3. Anticonvulsant and neurotoxicity screening results of II, IV and 2-substituted xanthone analogues (IIa, IVa) of II and IV.
Activity
Compound Dose MESa ScMETb Toxc
mg/kg 0.5 h 4 h 0.5 h 4 h 0.5 h 4 h
30 0/1 0/1 0/1 0/1 0/4 0/2
II 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 1/5 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IIa 100 2/3 0/3 0/1 0/1 0/8 0/4
300 1/1 0/1 0/1 0/1 4/4 0/2
30 0/1 0/1 1/5 0/1 0/4 0/2
IV 100 2/3 0/3 0/1 0/1 4/8 1/4
300 n.t. 0/1 0/1 0/1 2/4 0/2
30 1/1 1/1 1/1 0/1 0/4 1/2
IVa 100 n.t. n.t. n.t. n.t. 8/8 n.t.
300 n.t. n.t. n.t. n.t. 4/4 n.t.
a number of animals protected/ number of animals tested in the MES test
b number of animals protected/ number of animals tested in the scMet test
c number of exhibiting toxicity/ number of animals tested in the rotorod test
n.t. ñ compound was not tested
Figure 1. Antiarrhythmic activity of compounds II, III and IV in adrenaline-induced arrhythmia.
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Figure 2. Antiarrhythmic activity of compounds II, III and IV in barium-induced arrhythmia.
Figure 3. Antiarrhythmic activity of compounds II, III and IV in calcium-induced arrhythmia.
Figure 4. The influence of compounds II, III and IV on blood pressure of anaesthetized rat.
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longed P-Q and Q-T intervals and extended QRS
complex. (Table 2).
Adrenaline-, barium-, and calcium-induced arrhyth-
mias
The tested compounds did not prevent the
adrenaline-induced arrhythmia; but considerably
diminished arrhythmia causing blocks and extrasys-
toles. In adrenaline-induced model of arrhythmia the
most effective compound was compound IV. The
reference compounds ñ propranolol and quinidine ñ
administered 15 min before adrenaline, showed
insignificant preventive activity. In the barium
model of arrhythmia, compound II diminished mor-
tality by 43%. In calcium-induced model of arrhyth-
mia the strongest activity has also compound II. It
slightly intensified blocks (about 7%), but delayed
the extrasystoles (37%), highly prevented bigeminy
(70%, p < 0.01) and diminished (by 53%, p < 0.05)
mortality of animals (Figures 1-3). Propranolol and
quinidine used as referenced compounds did not
prevent against arrhythmias induced by barium or
calcium chlorides. 
The effect on the arterial blood pressure and respira-
tory movements
The investigated compounds had various influ-
ence on the blood pressure of normotensive rats. The
strongest hypotensive activity was showed by com-
pound II which diminished the arterial blood pres-
sure by about 40% during one hour observation.
Although immediately after intravenous administra-
tions the new xanthone derivatives weakly activated
the respiration, they did not have a significant influ-
ence on either the amplitude or frequency of respi-
ratory movements (Figure 4).
Searching for compounds with potential
antiepileptic activity we have noticed that several
circulatory drugs from the aminoalkanol or
aminoalkoxy groups, e.g. β-blockers (propranolol),
have also anticonvulsant properties. It is well known
that lipophilic drugs exhibit marked central action,
with possible indications in neurology and psychia-
try. Anticonvulsant effects of propranolol in various
seizure models were described (21). The present
results suggest that the anticonvulsant activity of
compounds II and IV may be related to their activi-
ty in adrenaline- and calcium chloride-induced
arrhythmia, but this is probably only one of several
factors involved in its activity. These data demon-
strated different potency of the new synthesized
xanthone derivatives in affecting functions of the
CNS and cardiovascular systems, which indicate the
importance of pharmacological examination of
newly synthesized compounds. The obtained results
of pharmacological tests suggest further examina-
tions to establish mechanism(s) of central activity of
the examined compounds, 2- and 4-substituted
derivatives of xanthone, and to estimate their poten-
tial therapeutic value. During the study of antiar-
rhythmic activity of some new congeners of
aminoisopropanoloxy xanthone derivatives the best
effect was demonstrated by compound II. The lack
of electrophysiological studies limited discussion of
the mechanism of action displayed by this com-
pound, however, the effect against such an aggres-
sive mediator like adrenaline strongly suggests to
extend the antiarrhythmic study of this compound in
the other models of arrhythmia and in situ and in
vivo experiments on rat isolated heart.
Anticonvulsant assays 
Preliminary anticonvulsant and neurotoxico-
logical tests of compounds II and IV have been pro-
vided by the Antiepileptic Drug Development
(ADD) Program (NIH, Bethesda, USA), by their
testing procedures which have been described earli-
er (22, 23). Phase I studies involved three tests in
mice: MES (maximal electroshock seizure), ScMet
(subcutaneous pentylenetetrazole seizure threshold)
and neurotoxicity (TOX). For the tested compounds
II and IV the anticonvulsant activity (MES, mice,
ip) was found only for IV, which in a dose of 100
mg/kg within 0.5 h after injection showed 75% anti-
convulsant protection with a 50% neurotoxicity. In
the ScMet screen for both compounds in the dose of
300 mg/kg within 0.5 h after administration, 20%
anticonvulsant protection was accompanied by neu-
rotoxic signs (50% for II and 100% for IV). When
comparing the anticonvulsant activity of compounds
II and IV with previously described 2-substituted
xanthones (IIa and IVa) containing the same 1-
piperazine moiety (12) we observed that these latter
were more active at appropriate doses (Table 3).
CONCLUSIONS
Based on the in vivo experiments, it seems that
(±)-1-[4-(hydroxyethyl)-1-(piperazinyl)]-3-(4-xan-
thonoxy)-2-propanol dihydrochloride (II) and (±)-1-
[4-(Benzyl)-1-(piperazinyl)]-3-(4-xanthoxy)-2-
propanol dihydrochloride (IV) are the most promis-
ing compounds, from which II demonstrated
hypotensive and antiarrhythmic activity (calcium-
induced model of arrhythmia). Compound IV
caused the significant anticonvulsant protection in
the MES screen mice in a dose of 100 mg/kg within
0.5 h after ip administration.
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The obtained preliminary in vivo results
encourage further search in the group of xanthone
derivatives as the agents possessing interesting bio-
logical activity.
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